Lixisenatide
Sources
registry, as of 2016-10-11Stale
https://clinicaltrials.gov/study/NCT00976937
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years. Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 319. Conditions Type 2 Diabetes Mellitus. The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index \[BMI\] greater than or equal to 30 kilogram per square meter \[kg/m\^2\]) type 2 diabetic patients Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24 Lixisenatide 18.4 Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24 Sitagliptin 11.9
ClinicalTrials.gov NCT00976937 protocol and results modules
registry, as of 2017-01-30Stale
https://clinicaltrials.gov/study/NCT02274740
Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients. Overall status TERMINATED. Phases PHASE2. Lead sponsor Sanofi. Enrollment 2. Conditions Type II Diabetes Mellitus. Primary Objective: To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in particular, the effects on plasma changes in triglycerides. Secondary Objectives: The effect of lixisenatide on the following postprandial lipids: apolipoprotein (APO) B48; fr
ClinicalTrials.gov NCT02274740 protocol and results modules
registry, as of 2017-11-29Stale
https://clinicaltrials.gov/study/NCT02745470
Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain. Overall status COMPLETED. Phases NA. Lead sponsor Seoul National University Hospital. Enrollment 30. Conditions Diabetes Mellitus. The aims this study is to explore the effect of a GLP-1 receptor agonist on the degree of brain activation and connectivity obtained by functional magnetic resonance imaging in lean and obese type 2 diabetes
ClinicalTrials.gov NCT02745470 protocol and results modules
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc
Lixisenatide is a synthetic analogue of human GLP-1, which acts as a GLP-1 receptor agonist.
DailyMed label description